Sales & Earnings In Brief
This article was originally published in The Tan Sheet
Executive Summary
Bausch & Lomb: Firm's revenues expected to grow in mid-single digits in FY 2004 based on continued strong sales from contact lens, lens care, pharmaceuticals categories, CEO Frank Zarrella projects during Oct. 30 earnings call. For the third quarter ended Sept. 27, B&L records 7.5% increase in lens care sales to $131.2 mil. as the ReNu brand continued to post impressive gains. Overall third quarter sales rose 9% to $508.8 mil.; net earnings totaled $32.3 mil. versus $9.4 mil. last year...
You may also be interested in...
Ester-E launch
Enhanced supplement Ester-E will begin rolling out in late spring 2004, Zila announces. The promotional campaign will begin at launch with national radio ads featuring spokesperson Larry King, and expand to television and print later in the year. A clinical trial measuring cardiovascular health as the primary endpoint is set to commence in May. Zila's Ester-E technology is based on a patented process for manufacturing tocopherol phosphate, obtained from Australia-based Vital Health Sciences. Zila recorded a 36% revenue increase on the strength of Ester-C sales in the fourth quarter ended July 31 (1"The Tan Sheet" Nov. 3, 2003, p. 15)...
Zila Nutraceuticals Ad Spend Increase Aims To Enhance Ester-C Brand
Zila Nutraceuticals will increase advertising spending 30% in fiscal 2004 to broaden awareness of its Ester-C branded vitamin C ingredient among consumers and retailers
Dial acquisitions?
Personal care firm may seek to acquire $200 mil.-$300 mil. brand in personal cleansing or household products categories, CEO Herbert Baum says during Prudential Securities Back-to-School Consumer Conference Sept. 5. Evaluation of candidates will begin in Q4. Dial is interested in brands that "might be unimportant to a bigger company," Baum says, citing P&G, Reckitt Benckiser, Colgate-Palmolive and Unilever. As of June 30, Dial has roughly $130 mil. in cash, which could be applied to deal. While Dial's board of directors recently reiterated company still is on the sales block, Baum notes potential sale is long-term goal and firm will "be going it alone for the foreseeable future"...